| Christopher Schelling |
Mr. Christopher Schelling is a President, Chief Executive Officer & Director at Acer Therapeutics, Inc. and a Secretary, Director & Head-Operations at Censa Pharmaceuticals, Inc. He is on the Board of Directors at Acer Therapeutics, Inc. and Censa Pharmaceuticals, Inc. Mr. Schelling was previously employed as a President, Chief Executive Officer & Director by Opexa Therapeutics, Inc., a Chief Executive Officer by Apanii Consulting LLC, a Chief Executive Officer & Director by Acer Therapeutics, Inc. /Old/, and an Executive Director-Strategic Marketing by BioMarin Pharmaceutical, Inc. He received his undergraduate degree from Carroll College (Montana). |
| Stephen J. Aselage |
Mr. Stephen J. Aselage is a Chairman at Acer Therapeutics, Inc., a President, Chief Executive Officer & Director at Retrophin, Inc. and a Chief Executive Officer at Kyalin Biosciences, Inc. He is on the Board of Directors at Retrophin, Inc. and Patara Pharma LLC. Mr. Aselage was previously employed as a Chairman by Desert Gateway, Inc., a Chief Executive Officer & Director by Retrophin LLC, a Chief Business Officer & Executive Vice President by BioMarin Pharmaceutical, Inc., an Executive VP-Global Commercial Operations by Cell Therapeutics, Inc., a Senior VP-North American Sales & Marketing by Genzyme Corp., a Senior VP-North American Sales & Marketing by SangStat Medical Corp., a Director-Sales & Marketing by Advanced Tissue Sciences, Inc., a Chairman by Acer Therapeutics, Inc. /Old/, a Sales Manager by Genentech, Inc., and a Sales Manager by Rorer Pharmaceuticals, Inc. He also served on the board at Opexa Therapeutics, Inc. and APT Pharmaceuticals, Inc. He received his undergraduate degree from the University of Notre Dame. |
| Harry S. Palmin |
Mr. Harry S. Palmin is a Chief Financial Officer at Acer Therapeutics, Inc. Mr. Palmin was previously employed as a Chief Financial Officer by Opexa Therapeutics, Inc. and a President, Chief Executive Officer & Director by Novelos Therapeutics, Inc. He received his undergraduate degree from Brandeis University and a graduate degree from Brandeis University. |
| Jefferson Davis |
Mr. Jefferson Davis is a Chief Business Officer at Acer Therapeutics, Inc. and a Partner at Extera Partners LLC. Mr. Davis was previously employed as a Senior Director-Corporate Development by Archemix Corp. He received his undergraduate degree from North Carolina State University and an MBA from Duke University. |
| William T. Andrews |
Dr. William T. Andrews, MD, is a Chief Medical Officer at Acer Therapeutics, Inc. Dr. Andrews was previously employed as a Senior Vice President-Business Development by Aegerion Pharmaceuticals, Inc. He received his undergraduate degree from Harvard University and a doctorate degree from Yale University. |
| Christopher Schelling |
Mr. Christopher Schelling is a President, Chief Executive Officer & Director at Acer Therapeutics, Inc. and a Secretary, Director & Head-Operations at Censa Pharmaceuticals, Inc. He is on the Board of Directors at Acer Therapeutics, Inc. and Censa Pharmaceuticals, Inc. Mr. Schelling was previously employed as a President, Chief Executive Officer & Director by Opexa Therapeutics, Inc., a Chief Executive Officer by Apanii Consulting LLC, a Chief Executive Officer & Director by Acer Therapeutics, Inc. /Old/, and an Executive Director-Strategic Marketing by BioMarin Pharmaceutical, Inc. He received his undergraduate degree from Carroll College (Montana). |
| Michelle Griffin |
Ms. Michelle Griffin is an Independent Director at Acer Therapeutics, Inc. She is on the Board of Directors at Acer Therapeutics, Inc., PhaseRx, Inc., Virginia Mason Health System and Virginia Mason Medical Center. Ms. Griffin was previously employed as a Chairman by Universal Cells, Inc., a Chief Financial Officer by OncoGenex Pharmaceuticals, Inc., a Chief Operating Officer by Trubion Pharmaceuticals, Inc., a Chief Financial Officer & Senior Vice President by Dendreon Corp., and a Chief Financial Officer by Corixa Corp. She also served on the board at Opexa Therapeutics, Inc. and Polynoma LLC. She received her undergraduate degree from George Mason University and an MBA from Seattle University. |
| Jason A. Amello |
Mr. Jason A. Amello, CPA, is an Independent Director at Acer Therapeutics, Inc. and a CFO, Treasure, SVP & Principal Accounting Officer at Akebia Therapeutics, Inc. He is on the Board of Directors at Acer Therapeutics, Inc. and New England Baptist Hospital. Mr. Amello was previously employed as a Chief Financial Officer, Treasurer & Executive VP by ZIOPHARM Oncology, Inc. and a Chief Accounting Officer, Senior VP & Controller by Genzyme Corp. He also served on the board at Opexa Therapeutics, Inc. He received his undergraduate degree from Boston College. |
| Hubert Birner |
Mr. Jason A. Amello, CPA, is an Independent Director at Acer Therapeutics, Inc. and a CFO, Treasure, SVP & Principal Accounting Officer at Akebia Therapeutics, Inc. He is on the Board of Directors at Acer Therapeutics, Inc. and New England Baptist Hospital. Mr. Amello was previously employed as a Chief Financial Officer, Treasurer & Executive VP by ZIOPHARM Oncology, Inc. and a Chief Accounting Officer, Senior VP & Controller by Genzyme Corp. He also served on the board at Opexa Therapeutics, Inc. He received his undergraduate degree from Boston College. |
| Luc Marengère |
Dr. Luc Marengère is Managing Partner at TVM Life Science Management, Inc. He is on the Board of Directors at CoLucid Pharmaceuticals, Inc., Albireo AB, Ixchelsis Ltd., Modulate Therapeutics, Inc. and PRCL Research Inc. Dr. Marengère was previously employed as Managing General Partner by VenGrowth Capital Partners, Inc., a Principal by Amgen, Inc., Co-President & Partner by CDP Capital Private Equity, an Investment Manager by Lumira Capital Corp., an Analyst by MedTech Partners, Inc., and a Principal by University Medical Discoveries, Inc. He also served on the board at Aegera Therapeutics, Inc., Argos Therapeutics, Inc., Cita Neuro Pharmaceuticals, Inc., Cytochroma, Inc., LymphoSign, Inc., Trillium Therapeutics, Inc. /Old/ and VisualSonics, Inc. He received his undergraduate degree from the University of Ottawa, a graduate degree from Queen's University and a doctorate degree from the University of Toronto. |
| John Michael Dunn |
Mr. John M. Dunn is an Independent Director at Acer Therapeutics, Inc. and a Secretary & General Counsel at Vital Therapies, Inc. He is on the Board of Directors at Acer Therapeutics, Inc., Agility Clinical, Inc., BIOCOM and CONNECT. Mr. Dunn was previously employed as an Executive Vice President by Biogen Idec New Ventures, Inc., a Secretary, Senior VP-Legal & Compliance by IDEC Pharmaceuticals Corp., and a Partner by Pillsbury Winthrop LLP. He also served on the board at Opexa Therapeutics, Inc. and Acer Therapeutics, Inc. /Old/. He received his undergraduate degree from the University of Wyoming and a graduate degree from the University of Wyoming. |
